STOCK TITAN
  1. Home
  2. News
  3. INAB

IN8bio Inc - INAB STOCK NEWS

Welcome to our dedicated news page for IN8bio (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IN8bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IN8bio's position in the market.

News
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) will present on Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product at the ASGCT 2024 Annual Meeting. The presentation focuses on novel production platforms and will take place on May 10th, 2024, in Baltimore, MD. The data will be available online post-presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
-
News
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Rhea-AI Summary
IN8bio, Inc. (INAB) to present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. CEO William Ho to discuss innovative gamma-delta T cell therapies. One-on-one meetings available for investors. Webcast to be archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences
-
News
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) announced promising preclinical data on its nsCAR platform, INB-300, showing improved selectivity in targeting leukemia cells while sparing healthy tissue. The technology aims to prevent off-target effects common in CAR-T therapies, potentially expanding treatment options for myeloid malignancies and solid tumors. Results presented at AACR 2024 revealed enhanced tumor killing capabilities without significant harm to healthy cells, indicating a 5.5x increase in selectivity. IN8bio plans to optimize the platform further for safer and more effective cancer treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
clinical trial
News
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
IN8bio, Inc. (INAB) reported positive results from Phase 1 studies of INB-100 in leukemia and INB-200 in GBM, showcasing durable remissions and extended progression-free survival. The company closed a private placement, securing $14.4 million in gross proceeds, strengthening its financial position. Dr. Corinne Epperly joined the Board of Directors. IN8bio highlighted upcoming pipeline milestones and events, including Phase 2 studies and potential IND applications. Financially, R&D expenses increased due to program advancements, while G&A expenses decreased. The company reported a net loss of $7.6 million for Q4 2023 and had a cash position of $21.3 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
earnings
-
News
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
Rhea-AI Summary
IN8bio, Inc. (INAB) presents new preclinical data on its non-signaling gamma-delta T cell CAR platform targeting CD-33 and CD-123 at the AACR Annual Meeting. The platform shows promise in selectively targeting cancer cells while sparing healthy tissue, potentially addressing 'undruggable' tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
conferences clinical trial
-
News
IN8bio to Present at Upcoming Investor Conferences
Rhea-AI Summary
IN8bio, Inc. (INAB) CEO to present at investor conferences in March, showcasing innovative gamma-delta T cell therapies. Webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
conferences
News
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
Rhea-AI Summary
IN8bio, Inc. (NASDAQ: INAB) announces a publication in Frontiers in Immunology discussing their novel gamma-delta T cell therapy for glioblastoma. The therapy, DeltEx Drug Resistance Immunotherapy (DRI), aims to enhance the immune response against GBM while minimizing toxicity to healthy tissues. IN8bio's Phase 1 trial shows promising results with a possible improvement in progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
News
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
Rhea-AI Summary
IN8bio, Inc. (NASDAQ: INAB) has announced positive data from clinical trials of its innovative gamma-delta T cell therapies INB-100, INB-200, and INB-400, with 100% durable complete remissions in leukemia patients and extended progression-free survival in glioblastoma multiforme patients. The company also closed a private placement, securing a cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags
none
-
News
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) presents positive updated data from its Phase 1 investigator-sponsored trial of INB-100 at the 65th ASH Annual Meeting & Exposition. 100% of treated leukemia patients remain alive, progression-free, and in durable complete remission. INB-100 shows the first-ever durable persistence of an allogeneic cellular therapy, with expansion and persistence of allogeneic gamma-delta T cells 365 days post-administration. The trial is being expanded, and additional data is expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.73%
Tags
clinical trial
News
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) has closed an initial round of fundraising, securing $14.4 million with the potential for an additional $32.5 million at increasing valuations. The company plans to use the proceeds to accelerate the development of its gamma-delta T cell therapies, extending its cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.29%
Tags
none
Stock INAB logo
IN8bio Inc

Nasdaq:INAB

INAB Rankings

#4786 Ranked by Market Cap
#4731 Ranked by Stock Gains
N/A Ranked by Dividends

INAB Stock Data

48.05M
24.46M
15.97%
37.34%
0.12%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
New York

About INAB

in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.